Validation and cross-cultural adjustment of PDQL-questionnaire, Spanish version (Ecuador) (PDQL-EV)

Cross-cultural validity, reliability, and psychometric properties of the persian version of the scales for outcomes in Parkinson's disease-psychosocial questionnaire

Objectives. Considering the influence of different motor and nonmotor features of Parkinson's disease (PD), it is important to evaluate the psychosocial functioning of the patients. For this purpose, the scales for outcomes in Parkinson's disease-psychosocial questionnaire (SCOPA-PS) has been previously designed. The aim of our study was to assess the cross-cultural validation and psychometric properties of the Persian version of the SCOPA-PS. Methods. One hundred and ten nondemented idiopathic Parkinson's disease (IPD) patients were consecutively recruited from an outpatient referral movement disorder clinic. Eligible patients filled up a number of questionnaires including the Persian version of SCOPA-PS during the face-to-face interview session and clinical examination to measure disease severity, nonmotor psychiatric symptoms, and health-related quality of life (HRQoL). Results. The highest and lowest correlation coefficients of internal consistency were reported for item 7 on "asking for help" (r = 0.765) and item 5 on "sexual problems" (r = 0.553). Cronbach's alpha reliability coefficient of the entire scale was 0.87 (95% CI: 0.83-0.90). The Hoehn and Yahr stage (r = 0.34, P < 0.001), Schwab and England ADL scale (r = -0.55, P < 0.001), anxiety (r = 0.64, P < 0.001), depression (r = 0.71, P < 0.001), and fatigue (r = 0.35, P < 0.001) were significantly correlated with the total score of the SCOPA-PS questionnaire. Conclusions. The Persian version of SCOPA-PS is a highly reliable and valid scale to measure psychosocial functioning in IPD patients with different sex, age-group, and educational level, which could be applied in future researches. Disease severity scales, depression, anxiety, fatigue, and different domains of HRQoL were all associated with psychosocial functioning in PD patients.

Translation, Cross-Cultural Adaptation, and Validation of the Parkinson's Disease Quality of Life Questionnaire (PDQL), the "PDQL-BR", into Brazilian Portuguese

Translate, culturally adapt, and validate the “Parkinson's Disease Quality of Life” (PDQL) BR, into Brazilian Portuguese. Fifty-two patients answered the PDQL-BR. Twenty-one patients answered the PDQL-BR again 14 days later. The UPDRS and HY scale was applied. Validation was evaluated using psychometric properties, checking the quality of the data, reliability, and validity. Quality of the data was evaluated based on occurrence of ceiling and floor effects. Reliability was evaluated based on: internal consistency of an item, homogeneity, and reproducibility. Validation was checked through the evaluation of convergent and discriminatory validation. There was no ceiling and floor effect. When evaluating reliability, items 20, 30, and 37 showed correlation of 0.34, 0.26, and 0.37, respectively, to your scale; the other items was higher than 0.4. The alpha Cronbach coefficient was higher than 0.7 for most domains. There was good reproducibility. There were no meaningful changes in the PDQL-BR translation and cross-cultural adaptation.

Determinants of quality of life in Brazilian patients with Parkinson's disease

Our objective was to identify determinants of health-related quality of life (HRQoL) in a cohort of Brazilian patients with Parkinson's disease (PD). Patients were evaluated by means of the Hoehn and Yahr staging (H&Y), Unified Parkinson's Disease Rating Scale (UPDRS), Schwab and England scale (S&E), Mini-Mental State Exam, Geriatric Depression Scale, and Hospital Anxiety and Depression Scale (HADS). HRQol was assessed using the MOS-Short-Form 36 (SF-36), the Parkinson's disease Questionnaire (PDQ-39), and the Scales for Outcomes in Parkinson's Disease-Psychosocial Questionnaire (SCOPA-PS). 144 patients were evaluated (mean age 62 years; 53.5% men; mean duration of illness 6.6 years; median H&Y, 2 (range: 1-4). Mean SCOPA-PS and PDQ-39 Summary Index (SI) were 39.2 and 40.7, respectively. Both, PDQ-39 and SCOPA-PS SIs correlated at a moderate level (r = 0.30-0.50) with H&Y, S&E, total UPDRS, HADS subscales, and SF-36 Physical and Mental Components. PDQ-39 and SCOPA-PS were closely associated (r = 0.73). HRQoL significantly deteriorated as H&Y progressed, as a whole. Mood disturbances, disability, motor complications, and education were independent predictors of HRQoL in the multivariate analysis model. In PD Brazilian patients, HRQoL correlated significantly with diverse measures of severity. Depression showed to be the most consistent determinant of HRQoL, followed by disability, motor complications, and education years. There was a close association between the PDQ-39 and SCOPA-PS summary scores.

Depression rating scales in Parkinson's disease: critique and recommendations

Depression is a common comorbid condition in Parkinson's disease (PD) and a major contributor to poor quality of life and disability. However, depression can be difficult to assess in patients with PD due to overlapping symptoms and difficulties in the assessment of depression in cognitively impaired patients. As several rating scales have been used to assess depression in PD (dPD), the Movement Disorder Society commissioned a task force to assess their clinimetric properties and make clinical recommendations regarding their use. A systematic literature review was conducted to explore the use of depression scales in PD and determine which scales should be selected for this review. The scales reviewed were the Beck Depression Inventory (BDI), Hamilton Depression Scale (Ham-D), Hospital Anxiety and Depression Scale (HADS), Zung Self-Rating Depression Scale (SDS), Geriatric Depression Scale (GDS), Montgomery-Asberg Depression Rating Scale (MADRS), Unified Parkinson's Disease Rating Scale (UPDRS) Part I, Cornell Scale for the Assessment of Depression in Dementia (CSDD), and the Center for Epidemiologic Studies Depression Scale (CES-D). Seven clinical researchers with clinical and research experience in the assessment of dPD were assigned to review the scales using a structured format. The most appropriate scale is dependent on the clinical or research goal. However, observer-rated scales are preferred if the study or clinical situation permits. For screening purposes, the HAM-D, BDI, HADS, MADRS, and GDS are valid in dPD. The CES-D and CSDD are alternative instruments that need validation in dPD. For measurement of severity of depressive symptoms, the Ham-D, MADRS, BDI, and SDS scales are recommended. Further studies are needed to validate the CSDD, which could be particularly useful for the assessment of severity of dPD in patients with comorbid dementia. To account for overlapping motor and nonmotor symptoms of depression, adjusted instrument cutoff scores may be needed for dPD, and scales to assess severity of motor symptoms (e.g., UPDRS) should also be included to help adjust for confounding factors. The HADS and the GDS include limited motor symptom assessment and may, therefore, be most useful in rating depression severity across a range of PD severity; however, these scales appear insensitive in severe depression. The complex and time-consuming task of developing a new scale to measure depression specifically for patients with PD is currently not warranted.

Two questionnaires for Parkinson’s disease: are the PDQ-39 and PDQL equivalent?

BACKGROUND

Although there is a wide range of specific health-related quality of life (HRQoL) measures for Parkinson's disease (PD), their psychometric attributes have never been compared.

OBJECTIVE

To compare the psychometric characteristics of the Parkinson's Disease Questionnaire-39 items (PDQ-39) and Parkinson's Disease Quality of Life Questionnaire (PDQL).

METHODS

The PDQ-39 and PDQL were simultaneously applied to 187 PD patients. Additional assessments included Hoehn and Yahr staging, Schwab and England Scale (SES), Unified Parkinson's Disease Rating Scale, Pfeiffer's Short Portable Mental Status Questionnaire (SPMSQ) and Hospital Anxiety and Depression Scale (HADS). Criteria for acceptability, scaling assumptions, reliability, construct validity and precision were drawn up.

RESULTS

Both the PDQ-39 and PDQL proved very similar in the following aspects: acceptability (no floor or ceiling effect); scaling assumptions (79.5% and 80% respectively of item-total correlations fitted the standard); internal consistency (PDQ-39 domains, alpha = 0.43-0.93; PDQL domains, alpha = 0.70-0.88); stability (intraclass correlation coefficient = 0.76-0.90); and internal validity (PDQ-39, r = 0.09-0.70; PDQL, r = 0.52-0.71). Convergent validity between the two questionnaires was moderate to high (r = -0.91 for summary indices). Precision was higher for the PDQ-39 Summary Index, and predictors were the same for both measures (mood disorders and disability).

CONCLUSIONS

Although the psychometric properties tested are quite similar in both measures, mainly insofar as summary indices are concerned, differences in some attributes and structural content should nevertheless be considered when comparing both instruments.

Independent validation of SCOPA–psychosocial and metric properties of the PDQ-39 Brazilian version

The objective of this study was to perform an independent validation of the Scales for Outcomes in Parkinson's Disease-Psychosocial questionnaire (SCOPA-PS) and assessment of the Parkinson's Disease Questionnaire (PDQ-39), Brazilian version. Patients were evaluated by means of the Unified Parkinson's Disease Rating Scale, Hoehn and Yahr staging (HY), Schwab and England scale, Mini-Mental State Examination, and Hospital Anxiety and Depression Scale. Health-related quality of life was evaluated using the MOS-Short Form 36 (SF-36), PDQ-39, and SCOPA-PS. One hundred forty-four patients were included (mean age, 62 years; 53.5% males; mean duration of illness, 6.6 years; HY, 1-4). Mean SCOPA-PS and PDQ-39 Summary Index (SI) were 39.2 and 40.7, respectively. The internal consistency of SCOPA-PS (Cronbach's alpha = 0.84; item-total correlation, 0.44-0.73) and PDQ-39 dimensions (alpha = 0.61-0.85; item-total correlation, 0.46-0.82) were satisfactory. Concerning the stability of the questionnaires, intraclass correlation coefficient (ICC) values were 0.71 for the SCOPA-PS and 0.86 for the PDQ-39 SI. ICC for PDQ-39 dimensions ranged from 0.52 (social support) to 0.80 (stigma). Standard error of measurement (SEM) values for each PDQ-39 dimension ranged from 0.49 (emotional well-being) to 17.52 (social support). SEM values for SCOPA-PS and PDQ-39 SI were 11.84 and 6.72, respectively. A significant correlation of SCOPA-PS and PDQ-39 SI with the SF-36 physical (-0.42 and -0.52, respectively) and mental components (-0.41) was found. Correlation between SCOPA-PS and PDQ-39 SI was 0.73 (all coefficients, P < 0.0001). The SCOPA-PS and PDQ-39, Brazilian versions, have satisfactory metric attributes.

Assessment of subjective health and health-related quality of life in persons with acquired or degenerative brain injury

PURPOSE OF REVIEW

Health-related quality of life is a new outcome variable in neurology. Several generic measures aim at assessing this variable in adults with neurological diseases. Disease-specific measures are still rare; however, individuals with neurological diseases frequently suffer from cognitive impairment, yet are often excluded from health-related quality of life investigations. When included in such studies, cognitive functioning is not monitored via neuropsychological evaluation, possibly leading to methodological problems. Papers from May 2004 until July 2005 are reviewed with respect to psychometric quality and information about persons after traumatic brain injury, stroke, Parkinson's disease or dementia.

RECENT FINDINGS

Several new cross-sectional and longitudinal outcome studies are reviewed. The Medical Outcome Study Short Form with 36 items, the Sickness Impact Profile and the Nottingham Health Profile were identified as the most frequently used measures in neurology. For traumatic brain injury, two new generic instrument validations (Life Satisfaction Index-A, Subjective Quality of Life Profile) and one internationally validated disease-specific development (Quality of Life after Brain Injury) were found; for stroke, one disease-specific tool (Burden of Stroke Scale) was identified. In Parkinson's disease, the disease-specific health-related quality of life measure Parkinson's Disease Questionnaire-39 is well validated. In dementia, three dementia-specific instruments (Quality of Life for Dementia, Quality of Life in Late-Stage Dementia Scale and Quality of Life in Alzheimer's Disease Scale) seem to be valid.

SUMMARY

In neurology, only a few measures have been developed and validated for respondents with cognitive impairment, often showing poorer validity results than studies involving healthy persons. Health-related quality of life assessment should therefore be validated in the specific diseases and, if necessary, combined with a neuropsychological evaluation and a disease-specific health-related quality of life measure.

Psychometric characteristics of the Parkinson's disease questionnaire (PDQ-39)—Ecuadorian version

This study sought to analyse certain metric characteristics of the Ecuadorian version (EV) of the Parkinson's Disease Questionnaire (PDQ-39 EV). A cross-sectional study was conducted on 137 Parkinson's disease (PD) patients attending a Movement Disorders Unit. Neurologists' assessments were based on Hoehn and Yahr (HY), Schwab and England and Unified Parkinson's Disease Rating Scales. Patients' self-evaluations included the Hospital Anxiety and Depression Scale, the Parkinson's Disease Quality of Life questionnaire (PDQL EV), and the PDQ-39 EV. Analyses for acceptability, internal consistency, precision, and construct validity (convergent and known-groups) were performed. Distribution of scores was satisfactory. There was no evidence of floor or ceiling effects. Although the alpha coefficient exceeded 0.70 for mobility, activities of daily living (ADL) and stigma, it was nevertheless low for bodily discomfort (0.48), communication (0.40), and social support (0.33). Fourteen items yielded low correlation coefficients (<0.40) with their respective dimensions. Correlation of social support and bodily discomfort with the Summary Index (SI) was modest (0.46 and 0.36, respectively). PDQ-39 EV SI convergent validity with the PDQL EV SI was very high (r(S)=-0.91), and known-groups validity proved satisfactory. Results agreed in part with those yielded by an international study, identifying specific flaws probably linked to socio-cultural influence.

Quality of life in patients with Parkinson's disease

We evaluated the quality of life (QoL) in 278 Indian patients with Parkinson's disease (PD) using PDQL questionnaire, with measures various aspects of health status in PD patients including parkinsonian symptoms, systemic symptoms, social and emotional functions. Apart from demographic and treatment details parkinsonian disability and stage was assessed by Hoehn and Yahr stage, Schwab and England scale and UPDRS scores. We conclude that female gender, presence of depression, low degree of independence, higher levodopa dose (>400 mg/day) and higher UPDRS activity of daily living score have the most detrimental impact on QoL in patients with Parkinson's disease. Depression was the most significant factor impairing the QoL and it needs to be treated.